BEAMSTART Logo

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

CNBC LogoCNBC1d ago

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. - CNBC

Quick Summary:

The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.


More Pictures

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. - CNBC (Picture 1)

or

Article Details

Category: EconomyBusiness

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-12-20 @ 21:40:33 (1 days ago)

News Timezone: GMT -5:00

News Source URL: cnbc.com

Language: English

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © CNBC

News ID: 24571171

View Article Analysis

About CNBC

CNBC Logo

Main Topics: EconomyBusiness

Official Website: cnbc.com

Update Frequency: 1 posts per day

Year Established: 2005

Headquarters: United States

News Last Updated: 1 days ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT -5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #5

Publisher Details

Frequently Asked Questions

Which news outlet covered this story?

The story "FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S." was covered 1 days ago by CNBC, a news publisher based in United States.

How trustworthy is 'CNBC' news outlet?

CNBC is a fully independent (privately-owned) news outlet established in 2005 that covers mostly economy and business news.

The outlet is headquartered in United States and publishes an average of 1 news stories per day.

It's most recent story was published 1 days ago.

What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #24571171
  • URL: https://beamstart.com/news/fda-approves-eli-lillys-weight-17347315146503

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2024 BEAMSTART. All Rights Reserved.